Rain Enhancement Technologies Holdco, Inc. (RAIN) Q1 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

And additional just-in-time sites will be opened as necessary from referrals from the Tempus and Carus Genomic Testing Services. We anticipate enrolling 65 patients across a range of solid tumors and using the same treatment protocol as in the Registrational Mantra Trial. That is with melidometan dosed at 260 milligrams in the three out of 14-day schedule. We anticipate an early data readout in the fourth quarter of this year and reporting patient responses, duration of response, and safety in approximately 10 evaluable patients. Based on the progress made with our Milodermatan clinical program thus far, we're looking forward to commencing two additional studies in the fourth quarter of this year. As Avinash mentioned, we anticipate starting the Mantra 3 study of Milodermatan in patients with Merkel cell carcinoma who are resistant or refractory to checkpoint inhibitor therapy. As a reminder, we believe the majority of patients with Merkel cell carcinoma, up to 80% of them, have a cancer induced by the polyomavirus, which induces MDM2 overexpression. We are also encouraged by data from other MDM2 inhibitor programs revealing monotherapy activity in the tumor setting. and hence believe that there is an opportunity for an MDM2 inhibitor program that may be better able to manage the on-target cytopenic toxicities. And finally, we're excitedly anticipating the initiation of our fourth study before year-end to evaluate our first combination regimen with milidimetan. This study, the Mantra 4 study, will evaluate the combination of milidimetan and rocistocentric, or atezolizumab. in a phase 1-2 study in approximately 30 patients with wild-type P53 advanced solid tumors that also exhibit loss of the CDKN2A gene. As a reminder, we believe loss of the gene CDKN2A and loss of i...